NASDAQ:CDNA CareDx (CDNA) Stock Price, News & Analysis $31.78 -1.58 (-4.74%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$31.37▼$33.2150-Day Range$13.54▼$33.9952-Week Range$4.80▼$34.84Volume161,901 shsAverage Volume917,190 shsMarket Capitalization$1.66 billionP/E RatioN/ADividend YieldN/APrice Target$29.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CareDx alerts: Email Address CareDx MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside13.1% Downside$29.00 Price TargetShort InterestHealthy7.05% of Float Sold ShortDividend StrengthN/ASustainability-0.66Upright™ Environmental ScoreNews Sentiment0.96Based on 15 Articles This WeekInsider TradingSelling Shares$1.15 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.49) to ($1.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.01 out of 5 starsMedical Sector395th out of 924 stocksMedical Laboratories Industry12th out of 18 stocks 1.3 Analyst's Opinion Consensus RatingCareDx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCareDx has only been the subject of 4 research reports in the past 90 days.Read more about CareDx's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.05% of the float of CareDx has been sold short.Short Interest Ratio / Days to CoverCareDx has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CareDx has recently decreased by 11.22%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCareDx does not currently pay a dividend.Dividend GrowthCareDx does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCareDx has received a 61.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "DNA sequencers", "Genomics analysis tools", and "Patient flow management systems" products. See details.Environmental SustainabilityThe Environmental Impact score for CareDx is -0.66. Previous Next 3.9 News and Social Media Coverage News SentimentCareDx has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 15 news articles for CareDx this week, compared to 3 articles on an average week.Search Interest14 people have searched for CDNA on MarketBeat in the last 30 days. This is an increase of 367% compared to the previous 30 days.MarketBeat Follows3 people have added CareDx to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CareDx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,148,450.00 in company stock.Percentage Held by InsidersOnly 4.20% of the stock of CareDx is held by insiders.Read more about CareDx's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CareDx are expected to grow in the coming year, from ($1.49) to ($1.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CareDx is -9.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CareDx is -9.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCareDx has a P/B Ratio of 6.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about CareDx's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsSecure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.Click here for the ticker >>> About CareDx Stock (NASDAQ:CDNA)CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.Read More CDNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDNA Stock News HeadlinesAugust 22 at 9:00 AM | insidertrades.comCareDx, Inc (NASDAQ:CDNA) Insider Sells $1,148,450.05 in StockAugust 20 at 2:41 PM | markets.businessinsider.comPositive Outlook for CareDx: Anticipating Revenue Growth and Manageable Legal ChallengesAugust 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. August 20 at 5:34 AM | americanbankingnews.comCareDx (NASDAQ:CDNA) Rating Increased to Buy at BTIG ResearchAugust 20 at 4:37 AM | msn.comBTIG Upgrades CareDx (CDNA)August 19 at 6:36 PM | msn.comApple, Lineage, OneStream initiated: Wall Street's top analyst callsAugust 18, 2024 | americanbankingnews.comCareDx (NASDAQ:CDNA) Trading 6.3% Higher August 17, 2024 | stockhouse.comCareDx Announces Transplant Community Secures Win Reaffirming Longstanding Medicare Coverage for AlloSure and AlloMap TestingAugust 22, 2024 | Crypto 101 Media (Ad)This Crypto Is Set to Explode in AugustWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Industry Giants are Investing Heavily in Blockchain Technology and THIS COIN is at the Heart of Their Strategy. It's a groundbreaking opportunity that could be poised for extraordinary gains. August 6, 2024 | msn.comCareDx, Inc (CDNA): Among the Best Organ Transplant and Diagnosis Stocks to Buy According to Hedge Funds?August 5, 2024 | finance.yahoo.comAnalysts Just Made A Substantial Upgrade To Their CareDx, Inc (NASDAQ:CDNA) ForecastsAugust 3, 2024 | finance.yahoo.comEarnings Beat: CareDx, Inc (NASDAQ:CDNA) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsAugust 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Strong Q2 Performance and Upbeat Outlook Drive CareDx’s Growth PotentialAugust 1, 2024 | finance.yahoo.comInvesting in CareDx (NASDAQ:CDNA) a year ago would have delivered you a 79% gainJuly 31, 2024 | seekingalpha.comCareDx, Inc 2024 Q2 - Results - Earnings Call PresentationJuly 19, 2024 | markets.businessinsider.comWhere CareDx Stands With AnalystsJuly 16, 2024 | prnewswire.comSHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CareDx, Inc. (NASDAQ: CDNA)July 15, 2024 | seekingalpha.comCareDx: Benefiting From Some CertaintySee More Headlines Receive CDNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CareDx and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today8/22/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryHealthcare Current SymbolNASDAQ:CDNA CUSIPN/A CIK1217234 Webwww.caredxinc.com Phone(415) 287-2300Fax415-287-2450Employees740Year FoundedN/APrice Target and Rating Average Stock Price Target$29.00 High Stock Price Target$40.00 Low Stock Price Target$18.00 Potential Upside/Downside-8.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($3.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-190,280,000.00 Net Margins-53.73% Pretax Margin-53.73% Return on Equity-53.65% Return on Assets-33.44% Debt Debt-to-Equity RatioN/A Current Ratio4.09 Quick Ratio4.03 Sales & Book Value Annual Sales$297.08 million Price / Sales5.57 Cash FlowN/A Price / Cash FlowN/A Book Value$5.02 per share Price / Book6.33Miscellaneous Outstanding Shares52,084,000Free Float49,896,000Market Cap$1.66 billion OptionableOptionable Beta1.78 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Abhishek Jain (Age 47)CFO & Principal Accounting Officer Comp: $425.58kDr. Peter Maag Ph.D. (Age 57)Executive Director Comp: $43.23kMr. Alexander L. Johnson (Age 50)President of Patient & Testing Services Comp: $547.43kMr. John Walter Hanna Jr. (Age 44)President, CEO & Director Ms. Marica Grskovic Ph.D.Chief Operating OfficerDr. Robert N. Woodward Ph.D.Chief Scientific OfficerMr. GS JhaSenior VP, Chief Information Officer & Chief Information Security OfficerJeffrey A. NovackGeneral CounselMs. Stacey FollonSenior VP & Head of Human ResourcesMr. Kashif RathoreChief of Patient & Digital SolutionsMore ExecutivesKey CompetitorsGenetronNASDAQ:GTHBurning Rock BiotechNASDAQ:BNRRadNetNASDAQ:RDNTPACS GroupNYSE:PACSOption Care HealthNASDAQ:OPCHView All CompetitorsInsiders & InstitutionsAlexander L JohnsonSold 34,231 sharesTotal: $1.15 M ($33.55/share)Driehaus Capital Management LLCBought 183,613 shares on 8/16/2024Ownership: 0.353%Millennium Management LLCBought 1,960,308 shares on 8/15/2024Ownership: 4.110%D. E. Shaw & Co. Inc.Sold 294,244 shares on 8/15/2024Ownership: 3.318%AQR Capital Management LLCSold 269,082 shares on 8/15/2024Ownership: 0.346%View All Insider TransactionsView All Institutional Transactions CDNA Stock Analysis - Frequently Asked Questions How have CDNA shares performed this year? CareDx's stock was trading at $12.00 on January 1st, 2024. Since then, CDNA shares have increased by 178.0% and is now trading at $33.36. View the best growth stocks for 2024 here. How were CareDx's earnings last quarter? CareDx, Inc (NASDAQ:CDNA) released its quarterly earnings data on Wednesday, February, 28th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by $1.97. The business's revenue was down 20.4% on a year-over-year basis. Who are CareDx's major shareholders? Top institutional shareholders of CareDx include ARK Investment Management LLC (10.95%), Sumitomo Mitsui Trust Holdings Inc. (4.95%), Millennium Management LLC (4.11%) and D. E. Shaw & Co. Inc. (3.32%). Insiders that own company stock include Reginald Seeto, Peter Maag, Alexander L Johnson, Michael Goldberg, Grace Colon, Ankur Dhingra and George Bickerstaff. View institutional ownership trends. How do I buy shares of CareDx? Shares of CDNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CareDx own? Based on aggregate information from My MarketBeat watchlists, some other companies that CareDx investors own include Block (SQ), Roku (ROKU), Exact Sciences (EXAS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA) and Enphase Energy (ENPH). This page (NASDAQ:CDNA) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Chri...Preserve Gold | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CareDx, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CareDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
